Lunai Bioworks

Update in progress

LNAI (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company serving the United States and the Netherlands. It operates through RENB, BioSymetrics, and RENC. The company is developing allogeneic dendritic cell vaccine candidates, including RENB-DC11 for solid tumors (with a focus on pancreatic cancer) and RENB-DC20 for breast cancer. It also pursues an AI multi-omics platform for early cancer detection and recurrence. Formerly Renovaro Inc., it rebranded in August 2025 and is headquartered in Los Angeles, California.

Company score

Sentiment: 0.23; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.17; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive